Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Wang

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Pharmacology|November 7, 2020
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumorsHaeseong Park, Kerry Williams, Nikolaos A Trikalinos, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 24, 2012
Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM studyMichael A Bolognese, Christence Stubbe Teglbjærg, Jose R Zanchetta, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancerThomas Regenbogen, Ling Chen, Kathryn Trinkaus, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Investigational New Drugs|August 7, 2012
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinomaAndrea Wang-Gillam, Stacey Plambeck-Suess, Peter Goedegebuure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2023
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based TherapyPatrick M Grierson, Rama Suresh, Benjamin Tan, et al.
Headache|May 20, 2022
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysisMessoud Ashina, Stewart J Tepper, Jan Lewis Brandes, et al.
American Journal of Clinical Oncology|July 26, 2021
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid TumorsManik Amin, Feng Gao, Gretel Terrero, et al.
Investigational New Drugs|August 14, 2014
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsA Craig Lockhart, Shankar Sundaram, John Sarantopoulos, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|November 7, 2020
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumorsHaeseong Park, Kerry Williams, Nikolaos A Trikalinos, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 24, 2012
Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM studyMichael A Bolognese, Christence Stubbe Teglbjærg, Jose R Zanchetta, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancerThomas Regenbogen, Ling Chen, Kathryn Trinkaus, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Investigational New Drugs|August 7, 2012
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinomaAndrea Wang-Gillam, Stacey Plambeck-Suess, Peter Goedegebuure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2023
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based TherapyPatrick M Grierson, Rama Suresh, Benjamin Tan, et al.
Headache|May 20, 2022
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysisMessoud Ashina, Stewart J Tepper, Jan Lewis Brandes, et al.
American Journal of Clinical Oncology|July 26, 2021
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid TumorsManik Amin, Feng Gao, Gretel Terrero, et al.
Investigational New Drugs|August 14, 2014
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsA Craig Lockhart, Shankar Sundaram, John Sarantopoulos, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Pageof 17